Tigermed Consulting, the clinical-stage CRO headquartered in Hangzhou, will stage an IPO on the ChiNext exchange, with pricing expected August 6; Covidien officially opened its China medical device R&D facility in Shanghai’s Caohejing Hi-Tech Park; Luqa Pharma of Hong Kong in-licensed China rights to a scar treatment from Stratpharma, a Swiss company; Kinex Pharma, a New York-state startup developing cancer drugs, received an investment from Dr. Manson Fok of Hong Kong; Barclays Bank raised its rating for the China healthcare space, moving to Positive on the sector; and Roche will hire an additional 1,000 people in China over the next year, as the company’s China revenues continue to climb. More details…. Stock Symbols: (NYSE: COV) (VX: ROG) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});